List of Kloxxado drug patents

Kloxxado is owned by Hikma.

Kloxxado contains Naloxone Hydrochloride.

Kloxxado has a total of 3 drug patents out of which 0 drug patents have expired.

Kloxxado was authorised for market use on 29 April, 2021.

Kloxxado is available in spray;nasal dosage forms.

Kloxxado can be used as use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.

The generics of Kloxxado are possible to be released after 26 August, 2034.

Can you believe KLOXXADO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10973814 HIKMA Liquid naloxone spray
Aug, 2034

(11 years from now)

US10722510 HIKMA Liquid naloxone spray
Aug, 2034

(11 years from now)

US11135155 HIKMA Liquid naloxone spray
Aug, 2034

(11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 April, 2021

Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients

Dosage: SPRAY;NASAL

More Information on Dosage

KLOXXADO family patents

13

United States

3

Japan

2

Canada

2

European Union

1

Morocco

1

Australia

1

China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic